Almirall invertirá 15 millones de dólares (13,5 millones de euros) para entrar en el capital de Suneva Medital. La farmacéutica catalana estará en el Consejo.
Almirall, controlada por los hermanos Gallardo, ha destacado que se trata de la "primera alianza estratégica de Almirall en el área de dermatología estética", y que entrará a formar parte del consejo de administración, si bien no precisa qué porcentaje del capital de Suneva pasará a controlar.
Regeneron Pharmaceuticals has risen to prominence in part by working with Sanofi to develop drugs for a number of diseases, most recently high cholesterol. Now the two are trying their hands at biotech’s hottest, and most crowded field, immuno-oncology, through a new wide-ranging deal that will see the two companies jointly invest more than $2 billion altogether.
Propeller Health has received FDA clearance to sell two new devices to help chronic respiratory disease patients track their medication usage and better follow their recommended treatment regimens.
Call9, a telemedicine startup in Y Combinator’s Spring 2015 cohort, is launching out of beta today to connect patients in emergency situations to doctors on demand.
If a nursing home patient exhibits warning signs of a heart attack, a nurse calls 911 and waits with the patient for an ambulance to arrive. The average ambulance wait time is 15 minutes, according to Call9 co-founder Timothy Peck, and this can be the difference between life and death.
Una treintena de cirujanos de la sanidad pública y privada han cobrado comisiones de hasta el 30% del precio de las prótesis vertebrales, de cadera y rodilla implantadas a sus pacientes. Así lo revelan documentos de la empresa Traiber a los que ha tenido acceso EL PAÍS, corroborados por exempleados de la compañía. Un juzgado de Reus (Tarragona) y la Guardia Civil, que ya investigaban a Traiber por la venta de prótesis caducadas, han puesto ahora el foco en estos pagos.
La compañía vasca especializada en biomedicina Innoprot ha desarrollado una tecnología basada en la aplicación de biosensores fluorescentes para facilitar el cribado molecular en la búsqueda de nuevos fármacos.
La firma, una spin-off de la UPV/EHU, ha diseñado una familia de bionsensores capaces de detectar actividad en los receptores GPCR, que están ubicados en la membrana celular y presentan una actividad alterada en enfermedades inflamatorias, cardiovasculares o cáncer.
Researchers who are developing miniature models of human organs on plastic chips have touted the nascent technology as a way to replace animal models. Although that goal is still far off, it is starting to come into focus as large pharmaceutical companies begin using these in vitro systems in drug development.
Tech isn’t the only sector receiving billions in venture capital funding. Healthcare and life sciences companies raised more than $8B from VC firms in 2014. And while tech exits may have slowed down, exits of VC-baked healthcare startups have been strong, especially IPOs: there were 61 in 2014 alone.
As VC dollars continue to flow into healthcare, we used CB Insights’ database to identify VC-backed companies treating conditions and diseases affecting different parts of the body.
We live in the digital age. You know that already. Two out of three Americans are now smartphone owners, and more than 86 percent of the population is connected online. But while digital has permeated everything from our social lives to how we work and how we shop, it is only starting to touch how we manage health.
